Pfizer announced highly positive late-stage trial results for its pill Braftovi, when combined with standard chemotherapy and cetuximab, in patients with an aggressive form of colorectal cancer. The combination therapy doubled the survival time for these patients compared to a standard treatment.
The trial data also showed that the Braftovi combination significantly cut deaths by 51% and reduced the risk of cancer progression by 47%. These substantial improvements in both overall survival and progression-free survival are clinically meaningful for patients facing this challenging disease.
These results are expected to support an expansion of Braftovi's approval label, positioning it as a potentially transformative treatment option for a specific patient population. The strong efficacy data underscore the drug's commercial potential in the oncology market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.